文摘
目的:确定类风湿性关节炎(RA)患者的风险增加感染和是否住院RA治疗的风险不同。方法:回顾性队列研究使用数据从医学和药学索赔管理式医疗保健数据库从1999年到2006年。共有24530名患者被包含在RA组;non-RA病人作为比较的随机样本组(n = 500000)。感染的住院率军团之间的比较。内嵌套病例对照分析RA组评估当前住院RA药物使用的影响感染的风险。结果:共有1993 RA患者和11977名non-RA患者经历了感染住院。第一次感染住院率较高的RA组(调整风险比= 2.03;95%可信区间(CI) 1.93 - -2.13)。在病例对照分析,当前使用生物疾病修饰治疗风湿病的药物(DMARD)与略增加感染住院的风险(利率比(RR) = 1.21; 95% CI 1.02-1.43]. Methotrexate and hydroxychloroquine were associated with decreased risk. Oral corticosteroid use increased risk (RR = 1.92; 95% CI 1.67-2.21), and there was a dose-related effect [< or = 5 mg/day: RR = 1.32 (95% CI 1.06-1.63), 6-10 mg/day: RR = 1.94 (95% CI 1.53-2.46), > 10 mg/day: RR = 2.98 (95% CI 2.41-3.69)]. CONCLUSION: These data confirm that individuals with RA are at increased risk of hospitalized infection compared to those without RA. Oral corticosteroid use was associated with a dose-related increase. Biological DMARD use was associated with slightly elevated risk; however, this may reflect confounding and channeling bias.